Orano USA’s Post

PanMediso Spotlight｜Big Moves for Nuclear Drug——Novartis April 30, 2024 - Novartis expanded its cooperation with PeptiDream on peptide discovery. PeptiDream's innovative Peptide Discovery Platform System (PDPS®) can identify and optimise novel macrocyclic peptides for potential radionuclide binding and therapeutic diagnostics. PeptiDream will receive the downpayment of $180 million and is likely to receive up to $2.71 billion in in milestone payments and sales splits! May 2 2024 - Novartis announced the acquisition of Mariana Oncology, gaining access to its pipeline of nuclear medicines, including breast, prostate and lung cancers, including the investigational small-cell lung cancer candidate MC-339. Novartis will make an upfront payment of USD 1 billion and an additional payment of USD 750 million upon achievement of predetermined milestones. As a radioligand therapy (RLT) R&D company, PanMediso Holdings will continue to concentrate on the latest industry trends, strengthen the international cooperation, and establish a close global partnership to make more innovative breakthroughs in personalized treatment and targeted therapy with aim of improving the treatment effect for patients. #Novartis #PeptiDream #MarianaOncology #nuclearmedicine #macrocyclicpeptide #pharmaceuticalcooperation 

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐂𝐮𝐫𝐢𝐮𝐦 - 𝐏𝐘𝐋𝐂𝐋𝐀𝐑𝐈™ 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧'𝐬 𝐌𝐚𝐫𝐤𝐞𝐭𝐢𝐧𝐠 𝐀𝐮𝐭𝐡𝐨𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧!   We are thrilled to announce that Curium has achieved another significant milestone. The European Commission has granted marketing authorization for PYLCLARI™ indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions using positron emission tomography in adults with prostate cancer.   Sakir Mutevelic MD, MSc, Chief Medical Officer at Curium commented, “The successful clinical development and granted marketing authorization of PYLCLARI™ in the EU confirms our mission to redefine the experience of cancer through our trusted legacy in nuclear medicine. We are looking forward to bringing PYLCLARI® to prostate cancer patients as well as to working together with health care professionals across the EU”   Learn more: https://lnkd.in/dSXqzfii #ProstateCancer #NuclearMedicine #PressRealease #News #Media #PSMA #PET #Pylclari #EuropeanComission #MarketingAuthorization 

The network of ICPO Centers is growing

Today Ariceum Therapeutics shares the exciting news that it has dosed its #firstpatient in its Phase Ib study with its first-in-class #radiopharmaceutical drug #satoreotide, targeting extensive stage small cell lung cancer.   Satoreotide is a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (#SST2), a cell surface protein and validated target often overexpressed in certain cancers including small cell lung cancer (#SCLC) and neuroendocrine tumours (#NETs).   The successful initiation of Ariceum's multicentre, open label Phase Ib study at the GenesisCare Theranostics Center in Murdoch, Australia is an important milestone for Ariceum in close collaboration with its partners in Australia and Europe.   Ariceum will present an abstract presentation on its Phase Ib study at the upcoming world leading European Association of Nuclear Medicine (EANM) on 10 September at 16.45 CEST in Vienna, Austria.   Read the full press release here to find out more about satoreotide and Ariceum's Phase Ib study: https://bit.ly/3ENsuah   #radiopharmaceuticals #cancer #neuroendocrinecancer #research

It's exciting to see all the attention that radiopharmaceutical cancer treatments are receiving. Recent achievements underscore the immense potential of targeted radiopharmaceutical therapies (TRT), which RBC Capital Markets sees as a $25 billion market opportunity. However, as the radiopharmaceutical field expands, so do the opportunities for advancing diagnostics and therapies across various diseases, not just cancer. From neurological disorders to cardiovascular conditions, it's a transformative era for nuclear medicine. https://lnkd.in/g9egw8Ku #Radiopharmaceuticals #NuclearMedicine #CancerTreatment

📰 News alert 📰 #Ariceum to present new preclinical data demonstrating the efficacy of its SST2 antagonist, #satoreotide, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024! Satoreotide demonstrates its potential to clinically outperform SST2-targeting agonists, strongly supporting further clinical development for the treatment of SST2 positive tumors such as Small Cell Lung Cancer (#SCLC) and Merkel Cell Carcinoma (#MCC). Key highlights below: 📢 SST2 antagonist, 225Ac-SSO110 (satoreotide), is multiple times more potent than SST2 agonist, 225Ac-DOTATATE 📢 Satoreotide demonstrated durable complete response in standard murine xenograft models of Small Cell Lung Cancer in animal models, versus tumor growth delay with 225Ac-DOTATATE Read more about Ariceum's game changing targeted radiopharmaceutical drug satoreotide and its promising data in the press release linked in the comments below. #lifesciences #biotech #radiopharmaceuticals #ATT001 #ATT002 #SNMMI2024

Ariceum Therapeutics is delighted to be presenting at the world leading 36th European Association of Nuclear Medicine (EANM) Congress in Vienna, Austria on 10 September at 16:45-16:55 CEST.   Ariceum will present on its Phase Ib study targeting extensive stage small cell lung cancer (ES #SCLC) following the recent announcement that its first #patient has been dosed with first-in-class lead molecule, #satoreotide.   The results from the study have the potential to demonstrate positive results from Ariceum's lead targeted systemic radiopharmaceutical product, satoreotide, in patients with extensive stage small cell lung cancer and improve the therapeutic effect of maintenance therapy.   Learn more about Ariceum's milestone Phase Ib study, here: https://bit.ly/3ENsuah   #radiopharmaceuticals #neuroendocrinecancers #systemictargetedtherapy #EANM23

Dive into this week's myth-busting adventure with AtomVie Global Radiopharma's (AtomVie's) "Nuclear Facts Unveiled" series!   Ever wondered how radioactive drugs like radiopharmaceuticals can treat cancer if radiation causes it? Let's uncover the truth together! Myth: If radiation causes cancer, how can radioactive drugs like radiopharmaceuticals be used to treat cancer? Fact: Radiopharmaceuticals are not only game-changers in diagnosis but also formidable allies in the fight against cancer and various other conditions. From pinpointing abnormalities to delivering targeted therapies, these innovative treatments are revolutionizing patient care! When injected into the patient’s bloodstream, the radiopharmaceutical travels to and delivers radiation directly to disease sites. Because it is highly selective in its ability to damage cancerous cells while limiting radiation exposure to healthy tissue, radiopharmaceuticals are a type of targeted therapy. Radiopharmaceuticals can save lives and improve a patient’s quality of life by providing diagnostic information crucial for appropriate medical care or delivering a much needed therapy. This benefit is usually discussed with the treating doctor as to how a nuclear medicine procedure can help the patient’s medical care. (source: https://lnkd.in/gKZvuFMn)   What do you think about this week's myth buster? Share your insights and experiences explaining the magic of radiopharmaceuticals to non-scientific audiences. And don't forget to spread the word by sharing this post with your network - Let's raise awareness of life-changing radiopharmaceuticals together! #AtomVieGlobalRadiopharma #NuclearFactsUnveiled #MythBusters #Radiopharmaceuticals #NuclearMedicine #Theranostics